ACEi
Showing 1 - 25 of 532
Nephrotic Syndrome Trial (Dapagliflozin and Standard therapy (ACEI or ARB)., Standard Therapy (ACEI or ARB).)
Not yet recruiting
- Nephrotic Syndrome
- Dapagliflozin and Standard therapy (ACEI or ARB).
- Standard Therapy (ACEI or ARB).
- (no location specified)
Jul 26, 2023
Entresto Versus ACEi/ARB in de Novo Heart Failure Patients
Completed
- de Novo Heart Failure
-
East Hanover, New JerseyNovartis
Jul 19, 2023
Covid-19 Trial in Hellerup, Herlev (Discontinuation of ACEi/ARB, Continuation of ACEi/ARB)
Completed
- Covid-19
- Discontinuation of ACEi/ARB
- Continuation of ACEi/ARB
-
Hellerup, Capital Region Of Denmark, Denmark
- +1 more
Jan 17, 2023
Hypertension, COVID-19 Trial in Kiev (Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, Direct renin
Completed
- Hypertension
- COVID-19
- Angiotensin converting enzyme inhibitor
- +2 more
-
Kiev, Please Select, UkraineMedical Practice Prof D.Ivanov
Feb 16, 2022
Diabetes, Type 2, Hypertension Trial in Buffalo (carvedilol, lisinopril)
Terminated
- Diabetes Mellitus, Type 2
- Hypertension
-
Buffalo, New YorkDiabetes - Endocrinology Center of Western New York
Feb 22, 2022
Compare Hospitalization Between Naive Sacubitril/Valsartan and
Completed
- Heart Failure
-
East Hanover, New JerseyNovartis Investigative Site
Dec 15, 2021
Chronic Kidney Disease, Blood Pressure, Angiotensin-converting Enzyme Inhibitor Trial in San Francisco (Continuation of ACEi
Active, not recruiting
- Chronic Kidney Disease
- +3 more
- Continuation of ACEi and/or ARBs
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 4, 2021
Diabetic Kidney Disease Trial in Herlev (ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide,
Recruiting
- Diabetic Kidney Disease
- ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
-
Herlev, DenmarkDepartment of Nephrology, Herlev and Gentofte Hospital
May 31, 2023
Influenza Vaccination, ACEI and ARB in Evolution of SARS-Covid19
Recruiting
- COVID19
- +3 more
- ACE inhibitor
- ARB
-
Terrassa, Barcelona, SpainHospital de Terrassa
Mar 9, 2022
Contrast-induced Nephropathy, Chronic Kidney Diseases, Ischemic Heart Disease Trial in Nablus (Continue ACEI or ARBs ( Enalapril
Recruiting
- Contrast-induced Nephropathy
- +2 more
- Continue ACEI or ARBs ( Enalapril , Ramipril , Valsartan , Candesartan, Losartan )
- Hold ACEI or ARBs
-
Nablus, West Bank, Palestinian Territory, occupiedAn-Najah National University Hospital
Feb 27, 2022
Hypertension, Atrial Fibrillation Trial in Beijing (Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI)
Not yet recruiting
- Hypertension
- Atrial Fibrillation
- Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
-
Beijing, Beijing, ChinaBeijing Tsinghua Chang Gung Hospital
Apr 23, 2023
IgA Nephropathy Trial in Shanghai (rituximab group)
Active, not recruiting
- IgA Nephropathy
- rituximab group
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Apr 9, 2023
Hypertension Trial in London (Preoperative ACEi/ARB management)
Completed
- Hypertension
- Preoperative ACEi/ARB management
-
London, Ontario, CanadaLondon Health Sciences Centre
Oct 21, 2021
Proteinuria, Kidney Diseases, Hereditary Nephropathy Trial in China (TCM+ Routine Therapy, Routine Therapy)
Not yet recruiting
- Proteinuria
- +2 more
- TCM+ Routine Therapy
- Routine Therapy
-
Hefei, Anhui, China
- +8 more
Feb 26, 2023
Sacubitril/Valsartan on Cardiac Function in Hypertensive
Recruiting
- Sacubitril/Valsartan
- +2 more
- Sacubitril / Valsartan Oral Tablet [Entresto]
- ACEI/ARB
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Aug 10, 2022
Myocardial Infarction With Non-obstructive Coronary Arteries Trial in Worldwide (Beta blocker, ACEI, ARB)
Recruiting
- Myocardial Infarction With Non-obstructive Coronary Arteries
- Beta blocker
- +2 more
-
Adelaide, Sout Australi, Australia
- +19 more
Sep 6, 2021
Cardio-Renal Syndrome Trial in Qingdao (Roxadustat;Sacubitril Valsartan Sodium Tablets;, EPO; ACEI / ARB)
Recruiting
- Cardio-Renal Syndrome
- Roxadustat;Sacubitril Valsartan Sodium Tablets;
- EPO; ACEI / ARB
-
Qingdao, Shangdong, ChinaDepartment of Nephrology, Affiliated Hospital of Qingdao Univers
Sep 13, 2021
Sacubitril/Valsartan in Improving Provider Performance in
Completed
- Heart Failure
- Sacubitril/valsartan
- ACEI or ARB and no sacubitril/valsartan
-
East Hanover, New JerseyNovartis Pharmaceuticals
Dec 15, 2021
Alport Syndrome Trial in Shanghai (Ramipril)
Not yet recruiting
- Alport Syndrome
-
Shanghai, ChinaXinhua Hospital, Shanghai Jiao Tong University School of Medicin
Nov 23, 2021
Proteinuria, Chronic Kidney Diseases Trial in Shanghai (ACEI treatment, Dapagliflozin+ACEI treatment)
Withdrawn
- Proteinuria
- Chronic Kidney Diseases
- ACEI treatment
- Dapagliflozin+ACEI treatment
-
Shanghai, Shanghai, ChinaChildren's Hospital of Fudan University
Dec 24, 2020
COVID-19, Cardiovascular Diseases Trial in Brazil, Canada, Mexico (Angiotensin converting enzyme inhibitor, Angiotensin II
Recruiting
- COVID-19
- Cardiovascular Diseases
- Angiotensin converting enzyme inhibitor
- Angiotensin II Receptor Blockers
-
Maceio, Alagoas, Brazil
- +30 more
Jan 13, 2023
Chronic Kidney Disease, Proteinuria, Children Trial in Multiple Locations (Finerenone (Kerendia, BAY94-8862))
Not yet recruiting
- Chronic Kidney Disease
- +2 more
- Finerenone (Kerendia, BAY94-8862)
-
Multiple Locations, Australia
- +22 more
Aug 10, 2022